Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$10.6 million.

  • Aytu Biopharma's Profit After Tax fell 144314.72% to -$10.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$25.1 million, marking a year-over-year decrease of 37811.9%. This contributed to the annual value of -$14.2 million for FY2025, which is 1048.98% up from last year.
  • As of Q4 2025, Aytu Biopharma's Profit After Tax stood at -$10.6 million, which was down 144314.72% from $2.0 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Profit After Tax ranged from a high of $4.0 million in Q1 2025 and a low of -$53.3 million during Q1 2022
  • In the last 5 years, Aytu Biopharma's Profit After Tax had a median value of -$6.9 million in 2022 and averaged -$10.4 million.
  • Within the past 5 years, the most significant YoY rise in Aytu Biopharma's Profit After Tax was 23834.43% (2025), while the steepest drop was 144314.72% (2025).
  • Quarter analysis of 5 years shows Aytu Biopharma's Profit After Tax stood at -$11.5 million in 2021, then skyrocketed by 42.04% to -$6.7 million in 2022, then skyrocketed by 109.25% to $619000.0 in 2023, then rose by 27.3% to $788000.0 in 2024, then plummeted by 1443.15% to -$10.6 million in 2025.
  • Its last three reported values are -$10.6 million in Q4 2025, $2.0 million for Q3 2025, and -$20.4 million during Q2 2025.